Haploidentical Stem Cell Transplantation for Relapsed-Refractory Hodgkin Lymphoma: A Multicentre Analysis

Hodgkin Lymphoma (HL) is a curable disease for most patients with standard treatment. However, patients with primarily refractory disease or relapsing after autologous stem cell tranplantation (ASCT) have poor prognosis. In this setting, reduced-intensity conditioning, allogeneic stem cell transplantation is a potentially curative approach, and, in the absence of an HLA-identical donor, haploidentical SCT (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy) has been evaluated with favorable preliminary results.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marcelo Lacerda, Celso Arrais Rodrigues, Andr é Domingues Pereira, Yana Novis, Marina Fonseca, Roberto Silva, Maria Cristina Macedo, Nelson Hamerschlak, Iracema Esteves, Jayr Schmidt Filho, Marina Nascimento, Vanderson Rocha Tags: Hodgkin Lymphoma Source Type: research